Focused on
Growth and Innovation
"Patients are at the heart of what we do"
Investor presentation
January 24, 2023
Table of contents
- Executive summary
- Portfolio
- Antifungal
- Cresemba® (isavuconazole)
- Antibiotic
- Zevtera® (ceftobiprole)
- Financials & Outlook
- Appendix
Focused on Growth and Innovation | Confidential/proprietary information of Basilea Pharmaceutica International Ltd, Allschwil - not for distribution | 2 |
Executive summary
Experienced leadership team
Focused on Growth and Innovation | Confidential/proprietary information of Basilea Pharmaceutica International Ltd, Allschwil - not for distribution | 4 |
At a glance
- Focus on the treatment of serious bacterial and fungal infections
- Recognized ability to establish and manage partnerships in both the development and commercial phase
- Cresemba® and Zevtera® - two revenue generating hospital anti-infective brands
- Commercial products complemented by programs which are in an earlier stage of development
- Reported preliminary profitability for 2022
- Listed on SIX Swiss Stock Exchange, SIX: BSLN
- Located in the Basel area life sciences hub, Switzerland
Focused on Growth and Innovation | Confidential/proprietary information of Basilea Pharmaceutica International Ltd, Allschwil - not for distribution | 5 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Basilea Pharmaceutica AG published this content on 24 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 January 2023 06:46:07 UTC.